Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female patients who fulfill the following criteria are eligible for inclusion.
- CMV D+/R- liver, kidney and heart recipient
- CMV R+ liver,kidney and heart recipients who have received thymoglobulin induction therapy.
- D+/R- and R+ lung transplant recipients.
- Able to give written informed consent
- Are willing and able to comply with the protocol
- Age >=18 years
Exclusion Criteria:
- Patient unwilling or unable to give informed consent
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Atul Humar, MD, University Health Network, Toronto
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 05-0265-AE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transplant
-
NCT04721288Not yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
NCT06025240RecruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant Dysfunction
-
NCT04837339RecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and Rejection
-
NCT04019353CompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant Dysfunction
-
NCT07194057Not yet recruitingLiver Transplant | Kidney Transplant | Transplant Complication
-
NCT06858098Not yet recruitingKidney Transplant | Kidney Transplant Recipient | Kidney Transplant Donor
-
NCT03380377CompletedKidney Transplant Rejection | Kidney Transplant; Complications | Antibody-mediated Rejection | Transplant Glomerulopathy | Transplant Glomerulopathy - Late Form | Transplant Glomerulopathy - Early Form
-
NCT01338779CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant Tolerance
-
NCT07305012RecruitingLiver Transplant | Kidney Transplant
-
NCT06288152RecruitingRenal Transplant | Kidney Transplant
Clinical Trials on Monitoring-blood samples drawn for CMV testing
-
NCT00242099Completed
-
NCT06901479Active, not recruitingPostoperative Delirium (POD)
-
NCT05772442Not yet recruitingHeart Transplant Rejection
-
NCT01871831Completed
-
NCT02404584Completed
-
NCT02158208CompletedHorton's Disease
-
NCT06763835Active, not recruitingAcute Coronary Syndromes | Plaque Rupture
-
NCT04313101UnknownICU Acquired Weakness | Thyroid Abnormalities
-
NCT01326273WithdrawnAllogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T Cells